報價延遲最少15分鐘:2025/01/11 17:07 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
46.62 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-5.38/-4.84
|
|
企業價值
6.32B
|
| 資產負債 |
|
每股賬面淨值
-0.12
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
7.53M
|
|
每股收益
0.07
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/01/11 17:07 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function. |